C
REGN icon

Certuity’s Regeneron Pharmaceuticals REGN Stock Holding History

Certuity’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$401K Sell
519
-118
-19% -$90.3K 0.03% 354
2025
Q4 		$492K Sell
637
-1,536
-71% -$1.04M 0.03% 276
2025
Q3 		$1.22M Buy
2,173
+214
+11% +$121K 0.08% 142
2025
Q2 		$1.03M Sell
1,959
-400
-17% -$223K 0.1% 119
2025
Q1 		$1.5M Buy
2,359
+945
+67% +$650K 0.16% 92
2024
Q4 		$1.01M Sell
1,414
-108
-7% -$90.6K 0.11% 114
2024
Q3 		$1.6M Sell
1,522
-196
-11% -$218K 0.17% 98
2024
Q2 		$1.81M Buy
1,718
+472
+38% +$458K 0.14% 89
2024
Q1 		$1.2M Buy
1,246
+142
+13% +$135K 0.11% 100
2023
Q4 		$970K Buy
1,104
+439
+66% +$362K 0.1% 111
2023
Q3 		$548K Buy
665
+83
+14% +$65.2K 0.06% 132
2023
Q2 		$418K Buy
582
+272
+88% +$210K 0.05% 162
2023
Q1 		$255K Buy
+310
New +$234K 0.04% 179

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Certuity's REGN Position: Q1 2026 in Review

Certuity reduced its Regeneron Pharmaceuticals (REGN) stake by 19% in Q1 2026, selling an estimated $90.3K and leaving 519 shares worth $401K. The position accounts for 0.03% of the portfolio, ranked #354.

Certuity first reported a position in REGN in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.81M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Certuity held 519 shares of Regeneron Pharmaceuticals worth $401K as of Q1 2026.
  • Certuity sold 118 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $90.3K.
  • Regeneron Pharmaceuticals made up 0.03% of Certuity's portfolio in Q1 2026, its #354 holding.
  • Certuity first reported a position in Regeneron Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Certuity's Regeneron Pharmaceuticals position peaked at $1.81M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Certuity's 13F filing for Q1 2026, filed 11 May 2026.